## Eliana Reyes

## List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/10574975/publications.pdf

Version: 2024-02-01

567281 610901 34 589 15 24 citations h-index g-index papers 35 35 35 863 docs citations times ranked citing authors all docs

#	Article	IF	Citations
1	Multicentre multi-device hybrid imaging study of coronary artery disease: results from the EValuation of INtegrated Cardiac Imaging for the Detection and Characterization of Ischaemic Heart Disease (EVINCI) hybrid imaging population. European Heart Journal Cardiovascular Imaging, 2016, 17, 951-960.	1.2	95
2	Guidelines in review: Comparison of ESC and ACC/AHA guidelines for the diagnosis and management of patients with stable coronary artery disease. Journal of Nuclear Cardiology, 2018, 25, 509-515.	2.1	56
3	High-Dose Adenosine Overcomes the Attenuation of Myocardial Perfusion Reserve Caused by Caffeine. Journal of the American College of Cardiology, 2008, 52, 2008-2016.	2.8	49
4	Ischemic Burden by 3-Dimensional Myocardial Perfusion Cardiovascular Magnetic Resonance. Circulation: Cardiovascular Imaging, 2014, 7, 647-654.	2.6	39
5	Myocardial perfusion scintigraphy in Europe 2007: a survey of the European Council of Nuclear Cardiology. European Journal of Nuclear Medicine and Molecular Imaging, 2012, 39, 160-164.	6.4	30
6	Sixty-four-slice computed tomography coronary angiography compared with myocardial perfusion scintigraphy for the diagnosis of functionally significant coronary stenoses in patients with a low to intermediate likelihood of coronary artery disease. Journal of Nuclear Cardiology, 2008, 15, 311-318.	2.1	29
7	Hybrid positron emission tomography–magnetic resonance of the heart: current state of the art and future applications. European Heart Journal Cardiovascular Imaging, 2018, 19, 962-974.	1.2	29
8	Attenuation of Adenosine-Induced Myocardial Perfusion Heterogeneity by Atenolol and Other Cardioselective $\hat{I}^2$ -Adrenoceptor Blockers: A Crossover Myocardial Perfusion Imaging Study. Journal of Nuclear Medicine, 2010, 51, 1036-1043.	5.0	24
9	Side effect profile and tolerability of adenosine myocardial perfusion scintigraphy in patients with mild asthma or chronic obstructive pulmonary disease. Journal of Nuclear Cardiology, 2007, 14, 827-834.	2.1	23
10	Comparison of ESC and ACC/AHA guidelines for myocardial revascularization. Journal of Nuclear Cardiology, 2017, 24, 1046-1053.	2.1	21
11	Guidelines in review: Comparison of the 2014 AHA/ACC guideline for the management of patients with non-ST-elevation acute coronary syndromes and the 2015 ESC guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation. Journal of Nuclear Cardiology, 2018, 25, 769-776.	2.1	21
12	CXCR2 Inhibition $\hat{a}\in$ a novel approach to treating CoronAry heart DiseAse (CICADA): study protocol for a randomised controlled trial. Trials, 2017, 18, 473.	1.6	20
13	Guidelines in review: Comparison of ESC and AHA guidance for the diagnosis and management of infective endocarditis in adults. Journal of Nuclear Cardiology, 2019, 26, 303-308.	2.1	20
14	Comparison of 64-slice cardiac computed tomography with myocardial perfusion scintigraphy for assessment of global and regional myocardial function and infarction in patients with low to intermediate likelihood of coronary artery disease. Journal of Nuclear Cardiology, 2008, 15, 497-502.	2.1	17
15	Guidelines in review: Comparison of the 2014 ACC/AHA guidelines on perioperative cardiovascular evaluation and management of patients undergoing noncardiac surgery and the 2014 ESC/ESA guidelines on noncardiac surgery: Cardiovascular assessment and management. Journal of Nuclear Cardiology, 2017, 24, 165-170.	2.1	15
16	Effect of body mass index on the efficacy, side effect profile, and plasma concentration of fixed-dose regadenoson for myocardial perfusion imaging. Journal of Nuclear Cardiology, 2011, 18, 620-627.	2.1	13
17	Myocardial perfusion scintigraphy: technical innovations and evolving clinical applications. Heart, 2012, 98, 353-359.	2.9	11
18	Caffeine reduces the sensitivity of vasodilator MPI for the detection of myocardial ischaemia: Pro. Journal of Nuclear Cardiology, 2016, 23, 447-453.	2.1	11

#	Article	IF	CITATIONS
19	Simultaneous 13N-Ammonia and gadolinium first-pass myocardial perfusion with quantitative hybrid PET-MR imaging: a phantom and clinical feasibility study. European Journal of Hybrid Imaging, 2019, 3, 15.	1.5	10
20	Acute myocardial infarction during adenosine myocardial perfusion imaging. Journal of Nuclear Cardiology, 2004, 11, 97-99.	2.1	9
21	Guidelines in review: Comparison between AHA/ACC and ESC guidelines for the management of patients with ventricular arrhythmias and the prevention of sudden cardiac death. Journal of Nuclear Cardiology, 2017, 24, 1893-1901.	2.1	7
22	Procedure guidelines for radionuclide myocardial perfusion imaging with single-photon emission computed tomography. Nuclear Medicine Communications, 2013, 34, 813-826.	1.1	6
23	Regadenoson stress for myocardial perfusion imaging. Future Cardiology, 2016, 12, 59-67.	1.2	6
24	Regadenoson myocardial perfusion scintigraphy for the evaluation of coronary artery disease in patients with lung disease: A series of five cases. Journal of Nuclear Cardiology, 2020, 27, 315-321.	2.1	6
25	Caffeine does not significantly reduce the sensitivity of vasodilator stress MPI: Rebuttal. Journal of Nuclear Cardiology, 2016, 23, 604.	2.1	5
26	Radiation dose from cardiac investigations: A survey of cardiac nurses' knowledge. British Journal of Cardiac Nursing, 2007, 2, 143-149.	0.1	4
27	The role of pharmacological stress testing in women. Journal of Nuclear Cardiology, 2016, 23, 997-1007.	2.1	3
28	Refining practice: TID metrics for CZT systems. Journal of Nuclear Cardiology, 2020, 27, 1190-1192.	2.1	3
29	Initial investigation of free-breathing 3D whole-heart stress myocardial perfusion MRI. Global Cardiology Science & Practice, 2020, 2020, e202038.	0.4	2
30	Regadenoson for myocardial perfusion scintigraphy. Expert Opinion on Medical Diagnostics, 2010, 4, 447-454.	1.6	1
31	Pharmacologic Stress Agents for Cardiac Imaging. Current Cardiovascular Imaging Reports, 2013, 6, 369-378.	0.6	1
32	How Should We Stress the Human Heart?. , 2013, , 15-28.		0
33	Regadenoson Stress in Patients with Airways Disease and Pulmonary Hypertension. Annals of Nuclear Cardiology, 2018, 4, 60-67.	0.2	0
34	Diagnosis of Coronary Artery Disease. , 2006, , 155-187.		O